Clomid for Women: Where It Works and Where It Does Not

It works for one specific problem: ovulation that is not happening. If your cycles are long, irregular or absent - most often because of polycystic ovary syndrome - clomiphene can get an egg released, and released eggs are how pregnancies start. That is the whole licensed indication, and it is a real one.

If you are already ovulating every month, clomiphene is being used for a different reason: not to correct something, but to try to improve the odds empirically, usually alongside insemination. That use has its own evidence, covered further down, and it is weaker.

The most useful thing to know before the first tablet is that for anovulatory PCOS, clomiphene is no longer the drug most guidelines reach for first. That is not a criticism of your prescriber - it is a change that happened in 2023, and the reason is set out next.

Because it produces more live births. The 2023 International Evidence-based Guideline for PCOS states, at its highest evidence grade, that letrozole should be the first-line pharmacological treatment for ovulation induction in infertile anovulatory women with PCOS who have no other infertility factor, and that letrozole should be used rather than clomiphene.

Two bodies of evidence sit behind that. Cochrane's 2022 review pooled 11 trials and 2,060 women on live birth and found letrozole ahead, with high-certainty evidence - about one extra live birth for every ten women treated. And the largest double-blind head-to-head trial, in 750 women over up to five cycles, found roughly one in four women reaching a live birth on letrozole against roughly one in five on clomiphene.

Two caveats that matter in India. First, letrozole is off-label for ovulation induction in many countries, which the guideline itself notes in recommendation 5.3.2; clomiphene is the drug with the licence. Second, clomiphene is not useless here - in the same guideline, clomiphene combined with metformin is preferred to clomiphene alone, and clomiphene is preferred to metformin alone. If you have been prescribed clomiphene, the question to ask is which of these routes was considered, not whether you have been given something worthless.

The underlying condition matters more than the drug choice - see PCOS and fertility and understanding anovulation.

This is the harder conversation, and it is where clomiphene is most often prescribed on the least secure ground.

The largest trial here randomised couples with unexplained infertility to up to four cycles of gonadotropin, clomiphene or letrozole. Roughly one couple in four on clomiphene had a live birth. Letrozole did not do better - a separate pooled analysis of 8 trials and 2,647 patients found no difference between the two oral drugs on live birth. So in unexplained infertility the letrozole advantage seen in PCOS does not appear; the choice between the oral drugs is closer to a coin toss.

The American Society for Reproductive Medicine's 2020 guideline on unexplained infertility concludes that treatment here is by necessity empirical, and that for most couples the best initial therapy is typically three or four cycles of ovarian stimulation with oral medication plus intrauterine insemination, followed by IVF for those it does not work for. Note what that sentence contains: a number of cycles, and a next step. An open -ended run of clomiphene is not what it describes.

What unexplained infertility means, and what has and has not been ruled out to reach that label, is worth reading before agreeing to empirical treatment.

Twins are the risk that changes outcomes, not the side effects. A twin pregnancy carries higher rates of prematurity, low birth weight and maternal complications than a singleton, and in India it also means a longer and costlier neonatal course if the babies come early.

The honest answer to "how likely" is that it depends who is being treated and how closely the cycle is watched, which is why one number cannot be quoted:

• In the original licensing studies, multiple pregnancy occurred in 7.98% of 2,369 pregnancies for which outcome data existed: 6.9% twin, 0.5% triplet, 0.3% quadruplet, 0.1% quintuplet - that is, roughly one multiple pregnancy in thirteen.
• Across 14 PCOS ovulation-induction trials and 2,247 participants, multiple pregnancy was 2.2% with SERMs versus 1.6% with letrozole - lower, because these were monitored trial cycles in a defined population.
• In the 750-woman PPCOS II trial, twin pregnancy was 7.4% with clomiphene and 3.4% with letrozole.
• In unexplained-infertility couples, 8 of 85 ongoing clomiphene pregnancies were multiple - all of them twins. In the gonadotropin arm 34 of 107 were multiple, and 10 of those were triplets.

The 2023 PCOS guideline draws the practical conclusion: because multiple pregnancy risk is increased with clomiphene, clomiphene cycles may require ultrasound monitoring. If you have been given a prescription with no scan planned, that is a fair thing to raise.

The label sets three stopping points, and all three are about futility rather than danger:

1. If ovulation has not happened after three courses, further clomiphene is not recommended and you should be reassessed.
2. If three ovulatory cycles have happened but no pregnancy, further treatment is not recommended.
3. Long-term cyclic therapy is not recommended beyond a total of about six cycles, including three ovulatory cycles.

The reasoning is that a drug which has done its job three times without a pregnancy has told you the problem is somewhere else. Continuing costs cycles of your time at the age you have, which is the resource that does not come back.

One safety point does scale with total exposure: the label warns that visual symptoms increase in incidence with increasing total dose or duration of therapy. Ovarian cancer is often cited as the reason for the six-cycle limit; the label's own position is that a causal relationship between ovarian hyperstimulation and ovarian cancer has not been determined.

Most of what clomiphene causes is uncomfortable and self-limiting. Hot flushes are the commonest; in the PPCOS II trial clomiphene caused them more often than letrozole did. Bloating, breast tenderness, mood change and nausea are all recognised.

Three things are worth a phone call the same day rather than waiting for the next appointment:

• Any visual change - blurring, spots, flashes of light. The label treats these as a reason to consider stopping, not as a nuisance, because they can persist.
• Pelvic pain with abdominal swelling, breathlessness, or a sudden weight gain. This is the picture of ovarian overresponse. Across 10 trials and 1,848 participants, OHSS occurred in 0.5% of women on a SERM and 0.5% on letrozole - uncommon, but it is the complication that can need admission.
• Any bleeding that was not expected. The label requires abnormal vaginal bleeding to be investigated before clomiphene is started, and it is a reason to stop and reassess if it appears during treatment.

What ovarian overresponse actually involves, and how it is prevented, is set out in IVF side effects: what OHSS is and how it is prevented.

Because it is an oestrogen-receptor drug, not a hormone. Clomiphene occupies oestrogen receptors in the hypothalamus so the brain reads oestrogen as low and raises FSH and LH - which is the intended effect. But the label notes it interacts with oestrogen-receptor-containing tissue throughout the body, including the endometrium, vagina and cervix, and may compete with oestrogen for those binding sites. That is the mechanism usually invoked when a lining looks thin or cervical mucus dries up on clomiphene - effects measured on the scan in a given cycle rather than predicted in advance.

That is the mechanistic reason clomiphene and letrozole behave differently outside the ovary: letrozole lowers oestrogen production for a few days and then clears, while clomiphene blocks receptors and one of its two isomers persists for over a month after a course. In the unexplained-infertility meta-analysis, mean serum oestradiol was significantly lower on letrozole than on clomiphene.

The pituitary hormones this is all aimed at are covered in the role of FSH, LH and estradiol in fertility.

No - not on the strength of this page, and not mid-cycle. Clomiphene is a licensed, cheap, oral treatment for the problem it treats, and there are good reasons a doctor in India prescribes it rather than letrozole: it has the licence, it is the drug the pharmacy will have, and where the guideline prefers letrozole it also says clinicians may use other agents where letrozole is not permitted.

What is reasonable is to go back with three questions: has letrozole been considered and ruled out, and why; how many cycles are we doing before we change plan; and will this cycle be monitored on ultrasound. None of those countermands a prescription. All three change what happens next.

It is also fair to say that reading that the drug you have just been given is second choice is deflating when you have finally started something. Second choice in a guideline is not the same as ineffective, and the gap between the two drugs is about one extra live birth in ten women treated - real, worth asking about, not a reason to lose faith in the cycle you are in.

Stated plainly, because the figures that circulate about this drug are mostly unsourced:

• That clomiphene increases live births compared with no treatment. Cochrane found a clinical-pregnancy benefit over placebo from 3 studies and 133 women, low-quality evidence, and no trial in that comparison reported live birth at all.
• That there is a single ovulation rate or pregnancy rate for clomiphene. The numbers differ by diagnosis, age, cycle count and whether IUI is added, which is why every figure on this page carries its denominator.
• That clomiphene causes ovarian cancer. The label states a causal relationship between ovarian hyperstimulation and ovarian cancer has not been determined. Not established, and not excluded either.
• That letrozole is better for everyone. In unexplained infertility, 8 trials and 2,647 patients found no difference in live birth between letrozole and clomiphene. The letrozole advantage is specific to anovulatory PCOS.
• That lifestyle change, acupuncture or supplements make clomiphene work better. No source retrieved for this article tested that question.

And sometimes the answer is not this drug. If cycles are regular, the tubes are open and the semen analysis is normal, the honest next step may be further testing or a different treatment rather than another month of tablets.